<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/158FD9ED-FBCE-4F87-BC2D-977F26C7F468"><gtr:id>158FD9ED-FBCE-4F87-BC2D-977F26C7F468</gtr:id><gtr:name>National Institute for Parasitic Diseases</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/DD06A8EB-2EFA-4AA6-9506-00256C806FB0"><gtr:id>DD06A8EB-2EFA-4AA6-9506-00256C806FB0</gtr:id><gtr:name>Ministry of Public Health, Lao PDR</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/93E07C2E-1C16-448B-A1F1-7D7EFBE1E2FD"><gtr:id>93E07C2E-1C16-448B-A1F1-7D7EFBE1E2FD</gtr:id><gtr:name>Swiss Tropical &amp; Public Health Institute</gtr:name><gtr:address><gtr:line1>Socinstrasse 57</gtr:line1><gtr:postCode>4002</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Switzerland</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/93E07C2E-1C16-448B-A1F1-7D7EFBE1E2FD"><gtr:id>93E07C2E-1C16-448B-A1F1-7D7EFBE1E2FD</gtr:id><gtr:name>Swiss Tropical &amp; Public Health Institute</gtr:name><gtr:department>Epidemiology and Public Health</gtr:department><gtr:address><gtr:line1>Socinstrasse 57</gtr:line1><gtr:postCode>4002</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Switzerland</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/93E07C2E-1C16-448B-A1F1-7D7EFBE1E2FD"><gtr:id>93E07C2E-1C16-448B-A1F1-7D7EFBE1E2FD</gtr:id><gtr:name>Swiss Tropical &amp; Public Health Institute</gtr:name><gtr:address><gtr:line1>Socinstrasse 57</gtr:line1><gtr:postCode>4002</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Switzerland</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/158FD9ED-FBCE-4F87-BC2D-977F26C7F468"><gtr:id>158FD9ED-FBCE-4F87-BC2D-977F26C7F468</gtr:id><gtr:name>National Institute for Parasitic Diseases</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DD06A8EB-2EFA-4AA6-9506-00256C806FB0"><gtr:id>DD06A8EB-2EFA-4AA6-9506-00256C806FB0</gtr:id><gtr:name>Ministry of Public Health, Lao PDR</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/8B9C2C0A-1ADB-4D5F-8C97-22F9F0531A3F"><gtr:id>8B9C2C0A-1ADB-4D5F-8C97-22F9F0531A3F</gtr:id><gtr:firstName>Somphou</gtr:firstName><gtr:surname>Sayasone</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/1A4DECCB-4D75-426E-A3DA-A9AE8CE9C65F"><gtr:id>1A4DECCB-4D75-426E-A3DA-A9AE8CE9C65F</gtr:id><gtr:firstName>Jennifer</gtr:firstName><gtr:surname>Keiser</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/9DA4C801-FC92-4013-8C56-24094A252F9C"><gtr:id>9DA4C801-FC92-4013-8C56-24094A252F9C</gtr:id><gtr:firstName>Kongsap</gtr:firstName><gtr:surname>Akkhavong</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/ECA26C5E-1227-4481-8184-0A1740E29E7E"><gtr:id>ECA26C5E-1227-4481-8184-0A1740E29E7E</gtr:id><gtr:firstName>Peter</gtr:firstName><gtr:surname>Odermatt</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/41860B97-046A-40F7-9F1D-6770B75AF963"><gtr:id>41860B97-046A-40F7-9F1D-6770B75AF963</gtr:id><gtr:firstName>Christoph</gtr:firstName><gtr:surname>Hatz</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/DA3EC609-FE92-4297-BAB5-FF2AE024D524"><gtr:id>DA3EC609-FE92-4297-BAB5-FF2AE024D524</gtr:id><gtr:firstName>Xiao-Nong</gtr:firstName><gtr:surname>Zhou</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G1100699"><gtr:id>D3440F52-FC51-443E-B6BE-5D88E9025CE5</gtr:id><gtr:title>Tribendimidine for the treatment of liver fluke infection in Southeast Asia</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G1100699</gtr:grantReference><gtr:abstractText>Millions of people are infected with the liver flukes Opisthorchis viverrini in Southeast Asia and Clonorchis sinensis in China. The diseases are associated with abdominal and hepato-biliar symptoms and serious manifestations such as obstructive jaundice and ascending cholangitis. Long-term consequences include the development of a fatal bile-duct cancer. Since there is currently only one drug available for the treatment of O. viverrini and C. sinensis, there is a need to develop novel trematocidal drugs. In a recent proof of concept trial with tribendimidine, a drug used in China for the treatment of roundworm infections, a high efficacy (based on changes in egg output after drug treatment) against infections with O. viverrini was observed. In addition, the drug was well tolerated. There is a need to follow up on these promising results. In the framework of 3 randomized trials the efficacy and safety of tribendimidine will be studied. First, we will study the dose-response of tribendimidine in O. viverrini patients and assess drug disposition. Second, once the ideal dose has been determined a phase 2b clinical trial will be conducted to compare the efficacies and safeties of tribendimidine with praziquantel. Finally, the efficacy and safety of tribendimidine against C. sinensis infections will be studied in a proof-of concept trial. The first two trial will be conducted in Laos, the third trial in China. In case tribendimidine has demonstrated adequate efficacy and safety in these trials we will pursue the registration of tribendimidine.</gtr:abstractText><gtr:technicalSummary>Human liver fluke infections are very common in Southeast Asia. Opisthorchis viverrini is endemic in Cambodia and Vietnam, but of significant public health importance in Lao People?s Democratic Republic (Laos) and Thailand. Clonorchis sinensis is endemic in the People?s Republic of China (China). Today, chemotherapy is the mainstay of control of opisthorchiasis and clonorchiasis, however only a single drug is available, praziquantel. Incentives to develop new trematocidal drugs have been minimal. Nonetheless, the dependence on a single drug for treatment and control of opisthorchiasis and clonorchiasis is highly critical, as drug resistant isolates are likely to develop. 
Tribendimidine is a widely used and registered nematocidal drug in China. A recent exploratory open-label trial conducted in Southern Laos compared tribendimidine (single dose of 200 mg in children below 14 years; 400 mg in children above 14 years) with praziquantel standard treatment regimen (75 mg/kg in 2 divided doses) for the treatment of O. viverrini infections. It was found that tribendimidine and praziquantel achieved cure rates of 70.4% and 56.0%, respectively. The corresponding egg reduction rates were 99.4% and 98.5%. Tribendimidine was well tolerated. Based on these encouraging findings we propose the following interlinked studies (i) to determine the appropriate dose of tribendimidine in the treatment of O. viverrini infections and to assess the key pharmacokinetic (PK) parameters of tribendimidine in diseased patients treated with different dosages of tribendimidine, (ii) to determine the safety and efficacy of tribendimidine in a phase 2b clinical trial in the treatment of O. viverrini in comparison to praziquantel standard treatment (75 mg/kg) and (iii) to determine the safety and efficacy of tribendimidine against C. sinensis in an exploratory open-label trial. 
In conclusion, our studies will for the first time assess the efficacy and safety of tribendimidine in clonorchiasis patients and thoroughly assess the dose-reponse and PK parameters in opisthorchiasis patients. Furthermore, we will assess the safety and efficacy of tribendimidine in a phase 2b tiral in comparison to standard praziquantel treatment. In case favourable results will be achieved a label extension in China, where the drug is registered, and a registration of tribendimidine in opisthorchiasis endemic countries will be pursued.</gtr:technicalSummary><gtr:fund><gtr:end>2014-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2012-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>257960</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Swiss Tropical &amp; Public Health Institute</gtr:collaboratingOrganisation><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:department>Department of Epidemiology and Public Health (EPH)</gtr:department><gtr:description>Swiss TPH</gtr:description><gtr:id>351F9C3E-76AC-4166-A82D-6A9279CFF32C</gtr:id><gtr:impact>Swiss-Lao partnership research project</gtr:impact><gtr:outcomeId>W3FPxSC4W51-1</gtr:outcomeId><gtr:partnerContribution>Technical support on trial implementation, laboratory processing for pharmacokinetic analysis and financial contribution for wage cost of their own researchers</gtr:partnerContribution><gtr:piContribution>Writing a trial concept note, trial proposal, trial protocol, and field work</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institute for Parasitic Diseases</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:description>NIPD</gtr:description><gtr:id>01DBB4BD-B188-4F23-91B4-076F0F59D7D5</gtr:id><gtr:impact>1) successfully conducted a trial on clonorchiasis and published a paper in the journal of Clin Infect Dis. 2013, PMID:23223597</gtr:impact><gtr:outcomeId>kzXbHgUghmm-1</gtr:outcomeId><gtr:partnerContribution>Field work preparation, obtained all required permissions, study area identification, identified local collaborators and trial operation</gtr:partnerContribution><gtr:piContribution>Technical support for conducting the trial on clonorchiasis, e.g., trial protocol development, field support and quality assurance</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Ministry of Public Health, Lao PDR</gtr:collaboratingOrganisation><gtr:country>Lao People's Democratic Republic</gtr:country><gtr:department>National Institute of Public Health</gtr:department><gtr:description>NIOPH</gtr:description><gtr:id>DC6F4600-0BF6-40BF-82F1-F43DF03EDE35</gtr:id><gtr:impact>Swiss-Lao partnership research project</gtr:impact><gtr:outcomeId>fnc4E6rkbGD-1</gtr:outcomeId><gtr:partnerContribution>Collaborating on concept note and proposal development, trial planning, and trial implementin</gtr:partnerContribution><gtr:piContribution>Collaborating on concept note and proposal development, trial planning, and trial implementing</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Participation in the development of Laotian National Guidelines for Helminth Control, Workshop organised by Ministry of Health</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>D1CF439E-2582-49D8-AAB0-B29A5AD372BF</gtr:id><gtr:outcomeId>546c755a1252e4.80173718</gtr:outcomeId><gtr:type>Implementation circular/rapid advice/letter to e.g. Ministry of Health</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Data collection and record was done by using a tablet and smart phone and by iusing all forms (questionnaires etc) in the commcare program (www.commcarehq.org). Data capturing was performed under a commcare ODK on cellphone and tablet.</gtr:description><gtr:id>E306EFB8-E70A-4FCF-8993-B9D6213728A7</gtr:id><gtr:impact>Minimize the mistake for data entry, ensuring the lost of data, safe time for data management</gtr:impact><gtr:outcomeId>QHMzsrGCTWx</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Commcare</gtr:title><gtr:type>Biological samples</gtr:type><gtr:url>http://www.commcarehq.org</gtr:url><gtr:yearFirstProvided>2013</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>BE989D72-3807-4A1E-9575-484142B5993B</gtr:id><gtr:title>Single-Ascending-Dose Pharmacokinetic Study of Tribendimidine in Opisthorchis viverrini-Infected Patients.</gtr:title><gtr:parentPublicationTitle>Antimicrobial agents and chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7c96689acf376f419b911dddea203152"><gtr:id>7c96689acf376f419b911dddea203152</gtr:id><gtr:otherNames>Duthaler U</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0066-4804</gtr:issn><gtr:outcomeId>5a9758d726e703.77530762</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>61DE0B8A-85A0-4321-B032-CA8A8E63D2FF</gtr:id><gtr:title>Efficacy and safety of tribendimidine against Opisthorchis viverrini: two randomised, parallel-group, single-blind, dose-ranging, phase 2 trials.</gtr:title><gtr:parentPublicationTitle>The Lancet. Infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bb48e1a58fcf047b66848f0e89f4e5b8"><gtr:id>bb48e1a58fcf047b66848f0e89f4e5b8</gtr:id><gtr:otherNames>Sayasone S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1473-3099</gtr:issn><gtr:outcomeId>5a9758d74d3765.63106889</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>932C4FA8-CE7E-4E70-A931-C5C0198861A3</gtr:id><gtr:title>Efficacy and safety of tribendimidine versus praziquantel against Opisthorchis viverrini in Laos: an open-label, randomised, non-inferiority, phase 2 trial.</gtr:title><gtr:parentPublicationTitle>The Lancet. Infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bb48e1a58fcf047b66848f0e89f4e5b8"><gtr:id>bb48e1a58fcf047b66848f0e89f4e5b8</gtr:id><gtr:otherNames>Sayasone S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1473-3099</gtr:issn><gtr:outcomeId>5a9758d777ba64.11629282</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>69DF5D78-2997-40A6-942A-CADF467446F9</gtr:id><gtr:title>Efficacy and safety of tribendimidine against Clonorchis sinensis.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b5e02ee5a2b7b22bf6a071f4b79437ea"><gtr:id>b5e02ee5a2b7b22bf6a071f4b79437ea</gtr:id><gtr:otherNames>Qian MB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>pm_24523_23_23223597</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6625909E-9BF1-46D5-A268-8D866F2B58F8</gtr:id><gtr:title>Population Pharmacokinetic Modeling of Tribendimidine Metabolites in Opisthorchis viverrini-Infected Adults.</gtr:title><gtr:parentPublicationTitle>Antimicrobial agents and chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/445ad2024dbd6d2f77b86d635fbab694"><gtr:id>445ad2024dbd6d2f77b86d635fbab694</gtr:id><gtr:otherNames>Vanobberghen F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0066-4804</gtr:issn><gtr:outcomeId>5a9758d6dcddd2.29000034</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G1100699</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>